Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announced the expiration of the waiting period under the HSR Act Waiting Period, in connection with Bristol Myers Squibb's tender offer to acquire all of the outstanding shares of RayzeBio stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. This satisfies one of the conditions necessary for the consummation of the transaction.
The expiration of the waiting period occurred on February 9, 2024. The offer will expire one minute after 11:59 p.m. New York City time, on February 22, 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.